Voyager Applications
ACE® Hernia Repair
The Problem
Abdominal wall reconstruction still relies on non-absorbable meshes, which remain permanently in the body and often cause chronic pain, infection, and foreign-body reactions, or costly biological meshes that are inconsistent and lack long-term strength. Surgeons are forced to choose between durability with high complication risks, or biocompatibility at unsustainable costs and inadequate performance.
Current Solutions
Lessons from PHASIX®
Phasix® mesh, developed by Tepha using PH4B polymer, proved the strong market demand for bioresorbable meshes, reaching $200M in revenue within three years of BD’s acquisition and becoming its fastest-growing surgical product. However, PH4B is costly to produce and less tunable, limiting its broader clinical and commercial potential. Phasix® validated the opportunity, but also highlighted the need for next-generation materials that deliver extended performance with scalable, cost-effective manufacturing.
Our Solution
Voyager’s PPCA-based surgical mesh offers reinforcement for 5–6 months, followed by complete resorption over 18–24 months—precisely matching physiological healing while minimizing long-term complications.
Built on a cost-efficient and tunable polymer, it is positioned to replicate and surpass Phasix’s success by offering hospitals a validated, lower-cost alternative without sacrificing performance. Regulatory approval is targeted for 2028 with commercial rollout shortly thereafter.
More Applications
Connect with us
